A split protocol of cisplatinum (CDDP) infusion in outpatients: Examination of pharmacokinetics

Journal of Applied Research

Volumn 4, Issue 2, 2004, Pages 215-221

  Kitamura, Yoichi ^a   Hayashi, Kazuhiko ^a   Yamada, Takuji ^a   Yamashita, Shingo ^a   Yamada, Michiyo ^a   Uchida, Kazumi ^a   Takasaki, Ken ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Cisplatinum; Pharmacokinetic study

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; DIURETIC AGENT; GIMERACIL; METOCLOPRAMIDE; ONDANSETRON; OTERACIL POTASSIUM; TEGAFUR; TS 1; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COLON CANCER; CORRELATION COEFFICIENT; CREATININE BLOOD LEVEL; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HUMAN; HYDRATION; INFUSION; KIDNEY FUNCTION; MALE; NAUSEA AND VOMITING; OUTPATIENT; PANCREAS CANCER; STOMACH CANCER;

EID: 6344237395     PISSN: 1537064X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Boku N, Ohtsu A, Shimada Y, et al. Phase I study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol. 1999;17:319-323.
2. Noda K, Nishiwaki Y, Kawahara M, et al and the Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346:346-385.
3. Pinzani V, Bressolle F, Haug IJ, Galtier M, Blayac JP, Balmès P. Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review. Cancer Chemother Pharmacol. 1994;35:1-9.
4. Takahashi A, Takagi M, Hishida H, et al. The pharmacokinetics of cisplatin and its influence on renal function according to different infusion methods. Jpn J Cancer Chemother. 1987;14(10):2944-2950.
5. Nagai N, Kinoshita M, Ogata H, et al. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients. Cancer Chemother Pharmacol. 1996;39:131-137.
6. Nagai N, Ogata H, Wada Y, et al. Population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: Analysis with the NONMEM program. J Clin Pharmacol. 1998;38:1025-1034.
7. Dana R, Kachhwaha VS. Comparison of on and intravenous hydration and diuretic, Choice for protecting cisplatin induced nephrotoxicity. Indian J Cancer. 1996;31:168-170.
8. Stewart DJ, Dulberg CS, Mikhael NZ, Redmond MD, Montpetit Vital AJ, Goel R. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol. 1997;40:293-308.
9. Schellens JHM, Ma J, Planting ASTh, et al. Relationship between the exposure to cisplatin. DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Brit J Cancer. 1996;73:1569-1575.
10. Kobayashi K, Shinbara A, Kamimura M, et al. Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small-cell lung cancer. Cancer Chemother Pharmacol. 1998;42:53-58.
11. Hayashi K, Imaizumi T, Uchida K, Kuramochi H, Takasaki K. High response rates in patients with pancreatic cancer using the novel oral fluoropyrimidine S-1. Oncol Rep. 2002;9:1355-1361.
12. Baba H, Yamamoto M, Endo K, et al. Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer. Gastric Cancer. 2003;6(suppl 1):45-49.
13. Tabata K, Yamaoka K, Kaibara A, Suzuki S, Terakawa M, Hata T. Moment analysis program available on Microsoft Excel. Xenobio Metabol and Dispos. 1999;14(4):286-293.
14. Yamamoto N, Tamura T, Maeda M, et al. The influence of ageing on cisplatin pharmacokinetics in lung cancer patients with normal organ function. Cancer Chemother Pharmacol. 1995;36:102-106.
15. Goodman M. Cisplatin: Outpatient and office hydration regimens. Sem Oncology Nursing. 1987;3(suppl 1):36-45.
16. Frogge MH. Streamlining outpatient cisplatin therapy to meet the challenges of today.
17. Sato A, Kurihara M, Masukawa M, et al. Preliminary study of fortnightly irinotecan hydrochloride plus cisplatin therapy in patients with advanced gastric and colorectal cancer. Cancer Chemother Pharmacol. 2001;47:380-384.
18. Niho S, Ohe Y, Kakinuma R, et al. Phase II study of docetaxel and cisplatin administered as three consecutive weekly infusions for advanced non-small cell lung cancer. Lung Cancer. 2002;35:209-214.